Hanx Biopharmaceuticals (Wuhan) Co., Ltd. (abbreviation: HANXBIO-B) disclosed a share repurchase on 13 April 2026 under its existing mandate.

The company acquired 43,000 H-shares on the Hong Kong Stock Exchange at prices ranging from HKD 29.18 to HKD 30.70, spending a total of HKD 1.29 million. The transaction represents 0.032 % of HANXBIO-B’s issued share capital (excluding treasury shares) as of the previous disclosure date (10 April 2026).

Following the buyback, the number of issued shares outstanding (excluding treasury shares) fell to 136.07 million, while treasury shares increased to 149,100. The total issued share count remains unchanged at 136.22 million.

The repurchase forms part of the mandate approved on 12 February 2026, which authorises HANXBIO-B to buy back up to 13.62 million shares. Cumulative repurchases under this mandate now total 149,100 shares, equivalent to 0.11 % of the company’s issued share base on the mandate date. In line with Hong Kong listing rules, the company is restricted from issuing, selling or transferring shares until 13 May 2026.